Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Processa Pharmaceuticals Inc. PCSA

MissionIRNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Serial Entrepreneur as New Chief Operating Officer

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, has appointed a new chief operating officer. Michael Floyd, a serial entrepreneur who has formed … Continue reading

Posted in MissionIRNewsBreaks, Processa Pharmaceuticals Inc. PCSA | Leave a comment

MissionIRNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Simply Wall St Article

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options, was featured in a Simply Wall St article. The piece highlights PCSA … Continue reading

Posted in Processa Pharmaceuticals Inc. PCSA | Leave a comment

MissionIRNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Closing of Public Offering

Processa Pharmaceuticals (NASDAQ: PCSA) has closed its previously announced underwritten public offering of 4,800,000 shares of common stock, which were offered to the public for $4 per share. The clinical-stage biopharmaceutical company, which focuses on the development of drug products … Continue reading

Posted in MissionIRNewsBreaks, Processa Pharmaceuticals Inc. PCSA | Leave a comment

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is “One to Watch”

Processa Pharmaceuticals aims to develop products where existing clinical evidence of efficacy already exists in the targeted unmet medical need condition with the drug itself or a drug with very similar pharmacology The Processa process focuses on the advancement of … Continue reading

Posted in Processa Pharmaceuticals Inc. PCSA | Leave a comment

MissionIRNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Pricing of $19.2M Public Offering, Nasdaq Uplisting

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options, today announced the pricing of an underwritten public offering of 4,800,000 shares … Continue reading

Posted in MissionIRNewsBreaks, Processa Pharmaceuticals Inc. PCSA | Leave a comment